Advertisement

Antispasmodics and Muscle Relaxants

  • Katherine D. TravnicekEmail author
Chapter

Abstract

Skeletal muscle relaxants are frequently prescribed for low back pain and other musculoskeletal pain with or after failure of first-line treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs). While there can be benefits of using skeletal muscle relaxants in the short term, the long-term effects are unclear. These medications are heterogeneous and not chemically related and have several important adverse effects that should be considered given their widespread utilization. In the United States, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, and orphenadrine are FDA approved for acute musculoskeletal conditions. Baclofen, tizanidine, and dantrolene are approved for spasticity. There is no clear evidence to show superiority of one muscle relaxant over another in managing acute low back pain, and most studies only evaluate results at 12 weeks or less. Most guidelines and current evidence support short-term use for all medications discussed in this chapter.

Keywords

Carisoprodol Carisoprodol abuse Chlorzoxazone Cyclobenzaprine Metaxalone Methocarbamol Orphenadrine Baclofen Tizanidine Dantrolene Diazepam Skeletal muscle relaxant efficacy Acute musculoskeletal conditions 

Recommended Reading

  1. 1.
    Alencar FG Jr, Viana PG, Zamperini C, Becker A. Patient education and self-care for the management of jaw pain upon awakening: a randomized controlled clinical trial comparing the effectiveness of adding pharmacologic treatment with cyclobenzaprine or tizanidine. J Oral Facial Pain Headache. 2014;28(2):119–27.CrossRefGoogle Scholar
  2. 2.
    Alpaslan C, Kahraman SA, Durmuslar C, Cula S. Comparative efficacy of four muscle relaxants on signs and symptoms of the myofascial pain syndrome associated with temporomandibular disorders: a randomized clinical trial. J Musculoskelet Pain. 2012;20(4):310–6.CrossRefGoogle Scholar
  3. 3.
    American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.CrossRefGoogle Scholar
  4. 4.
    Beebe FA, Barkin RL, Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther. 2005;12(2):151–71.CrossRefGoogle Scholar
  5. 5.
    Borenstein DG, Lacks S, Wiesel SW. Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clin Ther. 1990;12(2):125–31.PubMedGoogle Scholar
  6. 6.
    Browning R, Jackson JL, O’malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 2001;161(13):1613–20.CrossRefGoogle Scholar
  7. 7.
    Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manag. 2004;28(2):140–75.CrossRefGoogle Scholar
  8. 8.
    Chou R, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478–91.CrossRefGoogle Scholar
  9. 9.
    Chou R, Huffman LH, American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline [published correction appears in Ann Intern Med. 2008;148(3):247–248]. Ann Intern Med. 2007;147(7):505–514.Google Scholar
  10. 10.
    Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166:480–92.CrossRefGoogle Scholar
  11. 11.
    Cimolai N. Cyclobenzaprine: a new look at an old pharmacological agent. Expert Rev Clin Pharmacol. 2009;2(3):255–63.CrossRefGoogle Scholar
  12. 12.
    Dillon C, et al. Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES III). Spine. 2004;29(8):892–6.CrossRefGoogle Scholar
  13. 13.
    Ertzgaard P, Campo C, Calabrese A. Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen. J Rehabil Med. 2017;49:193–203.CrossRefGoogle Scholar
  14. 14.
    Fass JA. Carisoprodol legal status and patterns of abuse. Ann Pharmacother. 2010;44(12):1962–7.CrossRefGoogle Scholar
  15. 15.
    Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choiniere M. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome [Internet] The Canadian Fibromyalgia Guidelines Committee. Management. 2012;2012:1–6.Google Scholar
  16. 16.
    Fleuren JF, Voerman GE, Erren-Wolters CV, Snoek GJ, Rietman JS, Hermens HJ, Nene AV. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry. 2010;81(1):46–52.CrossRefGoogle Scholar
  17. 17.
    Forrester MB. Adult metaxalone ingestions reported to Texas poison control centers, 2000-2006. Hum Exp Toxicol. 2010;29(1):55–62.CrossRefGoogle Scholar
  18. 18.
    Friedman BW, Dym AA, Davitt M, et al. Naproxen with cyclobenzaprine, oxycodone/acetaminophen, or placebo for treating acute low back pain: a randomized clinical trial. JAMA. 2015;314(15):1572–80.CrossRefGoogle Scholar
  19. 19.
    Jackson J, Anania FA. Chlorzoxazone as a cause of acute liver failure requiring liver transplantation. Dig Dis Sci. 2007;52(12):3389–91.CrossRefGoogle Scholar
  20. 20.
    Johansson H, et al. Pathophysiological mechanisms involved in genesis and spread of muscular tension in occupational muscle pain and in chronic musculoskeletal syndromes: a hypothesis. Med Hypotheses. 1991;35:196–203.CrossRefGoogle Scholar
  21. 21.
    Kamen L, Henney HR III, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 2008;24:425–39.CrossRefGoogle Scholar
  22. 22.
    Khwaja SM, Minnerop M, Singer AJ. Comparison of ibuprofen, cyclobenzaprine or both in patients with acute cervical strain: a randomized controlled trial. CJEM. 2010;12(1):39–44.CrossRefGoogle Scholar
  23. 23.
    Leite FM, Atallah AN, El Dib R, Grossmann E, Januzzi E, Andriolo RB, et al. Cyclobenzaprine for the treatment of myofascial pain in adults. Cochrane Database Syst Rev. 2009;8(3):CD006830.Google Scholar
  24. 24.
    Malanga GA, Gwynn MW, Smith R, Miller D. Tizanidine is effective in the treatment of myofascial pain syndrome. Pain Physician. 2002;5(4):422–32.PubMedGoogle Scholar
  25. 25.
    Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008;9(12):2209–15.CrossRefGoogle Scholar
  26. 26.
    Malanga GA, Ruoff GE, Weil AJ, Altman CA, Xie F, Borenstein DG. Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design. Curr Med Res Opin. 2009;25(5):1179–96.CrossRefGoogle Scholar
  27. 27.
    Melloh M, Röder C, Elfering A, Theis JC, Müller U, Staub LP, et al. Differences across health care systems in outcome and cost-utility of surgical and conservative treatment of chronic low back pain: a study protocol. BMC Musculoskelet Disord. 2008;9:81.  https://doi.org/10.1186/1471-2474-9-81.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Otero-Romero S, Sastre-Garriga J, Comi G, Hartung H-P, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler J. 2016;22(11):1386–96.CrossRefGoogle Scholar
  29. 29.
    Peloso P, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie S, et al. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007;18(3):CD000319.Google Scholar
  30. 30.
    Preston KL, Guarino JJ, Kirk WT, Griffiths RR. Evaluation of the abuse potential of methocarbamol. J Pharmacol Exp Ther. 1989;248(3):1146–57.PubMedGoogle Scholar
  31. 31.
    See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78(3):365–70.Google Scholar
  32. 32.
    See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008;28(2):207–21.CrossRefGoogle Scholar
  33. 33.
    Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.CrossRefGoogle Scholar
  34. 34.
    Smith B, Peterson K, Fu R, McDonagh M, Thakurta S. Drug class review: drugs for fibromyalgia: final original report [Internet]. Portland: Oregon Health & Science University; 2011. [cited 2015 Jan 29]. (Drug Class Reviews). Available from: http://www​.ncbi.nlm.nih​.gov/pubmedhealth/PMH0010224/pdf/TOC​.pdf.Google Scholar
  35. 35.
    Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum [Internet]. 2004;51(1):9–13.CrossRefGoogle Scholar
  36. 36.
    van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;2:CD004252.Google Scholar
  37. 37.
    Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM, Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration. Spine. 2003;28(17):1978–92.CrossRefGoogle Scholar
  38. 38.
    Van Tulder MW, Koes B, Malmivaara A. Outcome of non-invasive treatment modalities on back pain: an evidence-based review. Eur Spine J. 2006;15(Suppl 1):S64–81.CrossRefGoogle Scholar
  39. 39.
    Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, Valaer C. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 2014;39(6):427–35.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pain Institute of NevadaLas VegasUSA

Personalised recommendations